Johnson & Johnson (NYSE:JNJ - Get Free Report) shares fell 0.3% during trading on Friday . The company traded as low as $156.08 and last traded at $156.73. 1,224,297 shares changed hands during trading, a decline of 86% from the average session volume of 8,854,394 shares. The stock had previously closed at $157.25.
Analyst Upgrades and Downgrades
Several research analysts recently issued reports on JNJ shares. StockNews.com raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, January 25th. Wolfe Research started coverage on Johnson & Johnson in a research note on Friday, November 15th. They issued an "outperform" rating and a $190.00 price objective on the stock. Barclays increased their price objective on Johnson & Johnson from $159.00 to $166.00 and gave the stock an "equal weight" rating in a research note on Tuesday, January 28th. Argus raised Johnson & Johnson to a "strong-buy" rating in a research note on Friday, January 24th. Finally, Stifel Nicolaus dropped their price objective on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a research note on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $170.67.
Read Our Latest Research Report on JNJ
Johnson & Johnson Price Performance
The company has a market cap of $376.08 billion, a PE ratio of 23.49, a price-to-earnings-growth ratio of 2.46 and a beta of 0.52. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The stock has a 50 day moving average of $147.87 and a 200-day moving average of $155.95.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The firm's quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the business posted $2.29 EPS. Equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.
Johnson & Johnson Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.18%. Johnson & Johnson's payout ratio is currently 74.59%.
Insider Buying and Selling at Johnson & Johnson
In related news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now owns 1,000 shares of the company's stock, valued at approximately $147,220. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.16% of the company's stock.
Institutional Investors Weigh In On Johnson & Johnson
A number of institutional investors have recently modified their holdings of JNJ. AMF Tjanstepension AB grew its position in shares of Johnson & Johnson by 14.2% during the 3rd quarter. AMF Tjanstepension AB now owns 425,261 shares of the company's stock valued at $68,985,000 after acquiring an additional 52,997 shares during the period. Alpha Financial Partners LLC acquired a new stake in shares of Johnson & Johnson during the 3rd quarter valued at about $209,000. Wealth Group Ltd. acquired a new stake in Johnson & Johnson in the 3rd quarter worth about $213,000. Creative Planning boosted its holdings in Johnson & Johnson by 4.3% in the 3rd quarter. Creative Planning now owns 988,403 shares of the company's stock worth $160,181,000 after buying an additional 41,082 shares during the last quarter. Finally, Swedbank AB boosted its holdings in Johnson & Johnson by 5.3% in the 3rd quarter. Swedbank AB now owns 2,215,108 shares of the company's stock worth $358,980,000 after buying an additional 111,570 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.
About Johnson & Johnson
(
Get Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Recommended Stories
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
